The global genome editing market size is expected to be worth USD 4.4 Billion in 2025. It can surge to a valuation of USD 10.22 Billion by 2032. The market is anticipated to exhibit a robust CAGR of 12.8% during the forecast period (2025-2032).
The market growth is driven by the presence of various genetic disorders and the demand for gene editing to cure diseases at their root cause. Technological strides in CRISPR/Cas9 and TALEN for successful gene editing can augur favorably for the market.
However, the high investment costs in research and development of genome editing and the commercialization of techniques are a considerable challenge for the market.
Key Market Insights
The genome editing market is characterized by investments by venture capital firms, editing for climate resilient crops, and partnerships between pharmaceutical companies and biotechnology firms.
The full report is now available for purchase: https://www.coherentmi.com/industry-reports/genome-editing-market
Genome Editing Market Report Coverage
|
Report Coverage |
Details |
|
Market Revenue in 2025 |
USD 4.4 Billion |
|
Estimated Value by 2032 |
USD 10.22 Billion |
|
Growth Rate |
12.8% |
|
Historical Data |
2020–2024 |
|
Forecast Period |
2025–2032 |
|
Forecast Units |
Value (USD Billion) |
|
Report Coverage |
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
|
Segments Covered |
|
|
Geographies Covered |
North America (U.S. and Canada), Latin America (Brazil, Argentina, Mexico, and Rest of Latin America), Europe (Italy, Spain, U.K., Germany, France, Russia, and Rest of Europe), Asia Pacific (China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific), Middle East (GCC Countries, Israel, and Rest of Middle East), and Africa (South Africa, North Africa, and Central Africa) |
|
Growth Drivers |
|
|
Opportunities |
|
|
Trends |
|
|
Restraints & Challenges |
|
Market Dynamics
The rise of theranostics or personalized medicine for the treatment of chronic diseases can drive the genome editing market growth. The approval of CRISPR therapies by government regulatory authorities can facilitate the market growth. On May 16, 2025, an infant in the U.S. was treated with CRISPR-Cas9to alter his genes for a condition called CPS1 deficiency, a recessive disorder that causes ammonia to accumulate in the blood. This can pave the way for more personalized treatments in the coming years.
Novel therapeutic solutions for gene mutations can create opportunities for the market. These could lead the way for combination therapies that combine biologics and genome editing. For instance, researchers at Osaka University, Japan, discovered a gene editing technique on July 09, 2025, that allowed mice to produce their own weight loss medication after a single injection.
Market Opportunity: Use of Genomic Techniques for Sustainable Crop Production
The use of gene-editing techniques for the production of climate-resilient crops can invite investments from private and government institutions. On May 30, 2025, the European Green Deal was gaining voice as researchers want genomic techniques to gain approval without authorization. This can be a gamechanger for farmers looking to increase their yields amid shrinking arable lands.
Market Challenge: Regulatory Uncertainty to Negatively Impact Market Growth
The lack of clarity in regulations towards genome editing can plague the efforts of researchers and biotechnology firms investing in the technology. The absence of preclinical assays and the lack of standardization of regulations across jurisdictions can limit the market growth.
Analyst’s View
Recent Developments
AIRNA, a U.S. biotechnology company, raised USD 155 million in a Series B round on April 01, 2025. The fresh capital will assist the company in leading the Phase II trial on its candidate, AIR-001, for the treatment of Alpha-1 antitrypsin deficiency (AATD).
Competitor Insights
Market Segmentation
Regional Insights
Related Reports :